Metformin Medreg

Metformin Hydrochloride, the active ingredient in Metformin Medreg, is a biguanide presented as an oral dosage form for oral use. It is used to lower elevated blood glucose levels in adults with type 2 diabetes mellitus and may be prescribed as part of a comprehensive diabetes management plan.

GNH USA supplies Metformin Medreg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Medreg belongs to the biguanide class and is employed to improve glycaemic control in disorders of glucose metabolism.

Type 2 diabetes mellitus: reduces hepatic glucose production and enhances peripheral insulin sensitivity to lower blood glucose levels. Prediabetes: helps delay progression to overt diabetes by improving insulin sensitivity. Polycystic ovary syndrome (off‑label): may improve insulin resistance and assist with menstrual regulation.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, often early in therapy. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: signs of liver injury. - Vitamin B12 deficiency: may develop with long‑term use. - Hypoglycaemia: uncommon when used alone but possible with other glucose‑lowering agents.

Metformin should be used with careful clinical monitoring to minimise risks.

Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter. Hepatic function monitoring: avoid use in patients with significant liver disease. Lactic acidosis vigilance: discontinue if patients develop unexplained acidosis, hypoxia, or severe infection. Elderly caution: start at lower doses and monitor for intolerance. Cardiac failure avoidance: contraindicated in severe congestive heart failure. Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Alcohol (excessive): enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - Warfarin: may require INR monitoring due to potential interaction.